ArticleFrontiers in pharmacology2024

Mex3a promoter hypomethylation can be utilized to diagnose HBV-associated hepatocellular carcinoma: a randomized controlled trial.

Jie-Ru Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.